233 related articles for article (PubMed ID: 22744888)
1. Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates.
Wen D; Liu A; Chen F; Yang J; Dai R
J Appl Toxicol; 2012 Oct; 32(10):834-42. PubMed ID: 22744888
[TBL] [Abstract][Full Text] [Related]
2. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
[TBL] [Abstract][Full Text] [Related]
3. Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish.
Zhu JJ; Xu YQ; He JH; Yu HP; Huang CJ; Gao JM; Dong QX; Xuan YX; Li CQ
J Appl Toxicol; 2014 Feb; 34(2):139-48. PubMed ID: 23307606
[TBL] [Abstract][Full Text] [Related]
4. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish.
Milan DJ; Peterson TA; Ruskin JN; Peterson RT; MacRae CA
Circulation; 2003 Mar; 107(10):1355-8. PubMed ID: 12642353
[TBL] [Abstract][Full Text] [Related]
5. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
6. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
7. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
8. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
9. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of zebrafish embryos as a model for assessing inhibition of hERG.
Mittelstadt SW; Hemenway CL; Craig MP; Hove JR
J Pharmacol Toxicol Methods; 2008; 57(2):100-5. PubMed ID: 18291682
[TBL] [Abstract][Full Text] [Related]
11. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
12. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Sintra Grilo L; Carrupt PA; Abriel H; Daina A
Eur J Med Chem; 2011 Aug; 46(8):3486-98. PubMed ID: 21624711
[TBL] [Abstract][Full Text] [Related]
13. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia.
Langheinrich U; Vacun G; Wagner T
Toxicol Appl Pharmacol; 2003 Dec; 193(3):370-82. PubMed ID: 14678746
[TBL] [Abstract][Full Text] [Related]
14. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
16. Computational investigations of hERG channel blockers: New insights and current predictive models.
Villoutreix BO; Taboureau O
Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
Gintant G
Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
[TBL] [Abstract][Full Text] [Related]
18. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Sanguinetti MC; Mitcheson JS
Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
[TBL] [Abstract][Full Text] [Related]
19. Effects of K openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs.
Testai L; Cecchetti V; Sabatini S; Martelli A; Breschi MC; Calderone V
J Pharm Pharmacol; 2010 Jul; 62(7):924-30. PubMed ID: 20636881
[TBL] [Abstract][Full Text] [Related]
20. Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Fujii M; Ohya S; Yamamura H; Imaizumi Y
J Biomol Screen; 2012 Jul; 17(6):773-84. PubMed ID: 22498908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
